| Date Filed | Type | Description |
| 10/05/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 10/02/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 08/21/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 08/14/2023 |
8-K
| Quarterly results |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 06/29/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 06/29/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/04/2023 |
8-K
| Quarterly results |
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/16/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 03/09/2023 |
8-K
| Quarterly results |
| 03/09/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/04/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 12/05/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 12/05/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 12/02/2022 |
8-K
| Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financi... |
| 11/23/2022 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 11/03/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/03/2022 |
8-K
| Quarterly results |
| 11/02/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 10/25/2022 |
8-K
| Quarterly results |
| 10/25/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 10/24/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 10/20/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 09/22/2022 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Cellectar Awarded $2 Million Grant to Expand Its Ongoing Phase 1study of Iopofosine I 131 in Pediatric Brain Tumors FLORHAM PARK, N.J., September 22, 2022 -- Cellectar Biosciences, Inc. , a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced it has been awarded $1.98 million in additional grant funding to expand its ongoing Phase 1study of iopofosine I 131 in children and adolescents with inoperable relapsed or refractory high grade gliomas . The grant was awarded by the National Institute of Health’ s National Cancer Institute based upon the initial signals of efficacy in the Phase 1study, which is an international, open-label, dose escalation, safety study. The funding allows for an expansion ..." |
|
| 09/13/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/05/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/05/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/05/2022 |
8-K
| Quarterly results |
| 07/21/2022 |
8-K
| Quarterly results |
| 06/27/2022 |
8-K
| Quarterly results |
| 06/07/2022 |
DEFR14A
| Form DEFR14A - Revised definitive proxy soliciting materials: |
|